Join the Oncology Voice Network. Join for Free
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
City of Hope Academic Clinical Research CAR T‑cell therapy gene therapy

What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.


Share This Article



Summary

In this episode, Leo Wang, M.D., Ph.D., pediatric oncologist, Clinical Director of the Gene Therapy Program and Director of the City of Hope Alpha Clinic, discusses the realities of caring for children with cancers that still have few effective treatments. He reflects on what it takes to begin changing those realities for patients and families.

While many childhood leukemias are now highly curable, Dr. Wang explains children with certain aggressive brain tumors still face the same outcomes they did a decade ago. This lag in progress is what drives his work today investigating CAR T‑cell therapy gene therapy in early phase clinical trials.

Throughout the conversation, Dr. Wang returns to the idea that progress in pediatric cancer care depends on collaboration across institutions, bringing together patient care, careful study and shared commitment across the research community. For him, the work centers on honoring the trust families place in the field and steadily moving discoveries from the lab to children who need more options and more time.

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Partner Avatar Monty Pal

Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.

Podcast
The Long Game of Cancer Genomics: John Carpten, Ph.D., on Building Precision Oncology that Reaches Patients
Partner Avatar Monty Pal

The Long Game of Cancer Genomics: John Carpten, Ph.D., on Building Precision Oncology that Reaches Patients

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN